HYUNDAI BIOLAND Co.Ltd vs NeoPharm CO.: Fair Value & Quality
Both stocks run through our valuation models. Here is how HYUNDAI BIOLAND Co.Ltd (052260) and NeoPharm CO. (092730) compare, as of Sep 14, 2026.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
NeoPharm CO. leads: 0 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
What the models say
How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.
▲above the price, more than 15% above ●close to the price, 85% to 115% of the price ▼below the price, more than 15% below
| Model family | HYUNDAI BIOLAND Co.LtdPrice KRW 3,980 | NeoPharm CO.Price KRW 21,600 |
|---|---|---|
| DCF Models | ▲+82%above the priceKRW 7,246 | ▲+98%above the priceKRW 42,724 |
| Earnings-Based | ▼-97%below the priceKRW 103 | ●+9%close to the priceKRW 23,480 |
| Multiples | ▼-21%below the priceKRW 3,148 | ▲+35%above the priceKRW 29,247 |
| Asset-Based | ▼-24%below the priceKRW 3,041 | ▼-61%below the priceKRW 8,368 |
| Growth DCF | ▲+103%above the priceKRW 8,097 | ▲+62%above the priceKRW 35,001 |
| Economic Profit | ●-3%close to the priceKRW 3,874 | ●-5%close to the priceKRW 20,625 |
| Growth Earnings | ▼-96%below the priceKRW 151 | ▲+66%above the priceKRW 35,793 |
| Minimum | ▼-97%below the priceKRW 103 | ▼-61%below the priceKRW 8,368 |
| Maximum | ▲+103%above the priceKRW 8,097 | ▲+98%above the priceKRW 42,724 |
| Median | ▼-21%below the priceKRW 3,148 | ▲+35%above the priceKRW 29,247 |
| Geometric mean | ▼-58%below the priceKRW 1,653 | ▲+16%above the priceKRW 25,138 |
Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.
HYUNDAI BIOLAND Co.Ltd: 11 of 24 models see the stock below the current price.
NeoPharm CO.: 5 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
HYUNDAI BIOLAND Co.Ltd · Consumer Staples
NeoPharm CO. · Consumer Staples
Bottom line
As of Sep 14, 2026, Fair Value Calculator sees NeoPharm CO. as the more attractively valued of the two: HYUNDAI BIOLAND Co.Ltd trades at KRW 3,980 versus a fair value of KRW 2,740 (-31%), while NeoPharm CO. trades at KRW 21,600 versus KRW 35,793 (+66%).
NeoPharm CO. has the higher quality score (67/100).
See the full analysis →More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Related to HYUNDAI BIOLAND Co.Ltd
Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor ManufacturingSee the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.